CCL17 and neoplasm: Several reports have implicated the CCL17/22-CCR4 pathway and tumor-derived TGF-β in Treg recruitment and activation respectively in the tumor microenvironment [30, 31], suggesting that inhibition of the CCL17/22-CCR4 pathway could substantially modulate the tumor accumulation of Tregs.